Advertisement

World Journal of Urology

, Volume 36, Issue 2, pp 305–317 | Cite as

The effect of onabotulinumtoxinA according to site of injection in patients with overactive bladder: a systematic review and meta-analysis

  • Jung Ki Jo
  • Kyu Nam KimEmail author
  • Dong Won Kim
  • Yong Tae Kim
  • Ji Yoon Kim
  • Ji Yeon Kim
Original Article

Abstract

Purpose

This study assessed the efficacy and safety of onabotulinumtoxinA according to injection site for treatment of overactive bladder.

Methods

A systematic literature review located randomized controlled trials of onabotulinumtoxinA treatment for neurogenic detrusor overactive bladder and idiopathic overactive bladder in adults. We searched MEDLINE, EMBASE, and the Cochrane Controlled Trials Register using the Ovid platform. Meta-analysis was based on Cochrane Review Methods.

Results

Eight studies (419 participants) were included. Trigone-including injection demonstrated a significant improvement in symptom score (SMD = − 0.53, 95% CI − 1.04 to − 0.02, P = 0.04, I 2 = 78%), higher complete dryness rates (OR = 2.19 patients, 95% CI 1.32–3.63, P = 0.002, I 2 = 41%), and lower frequency of incontinence episodes (WMD = − 0.85 per day, 95% CI − 1.55 to − 0.16, P = 0.02, I 2 = 87%) in patients. Comparing trigone-including injection to trigone-sparing injection, lower detrusor pressure (WMD = − 2.55 cm H2O, 95% CI − 4.16 to − 0.95, P = 0.002, I 2 = 0%) and higher volume at first desire to void (WMD = 17.54 ml, 95% CI 1.00–34.07, P = 0.04, I 2 = 0%) were observed with trigone-including injection. Between intradetrusor and suburothelial injection sites, there were no differences in efficacy or safety regarding the incidence of vesicoureteral reflux, hematuria, general weakness, bladder discomfort, large post-void residual, and urinary tract infection.

Conclusion

Trigone-including onabotulinumtoxinA injection has superior efficacy to trigone-sparing injection without increased complications. The depth of injection does not influence the efficacy or safety of onabotulinumtoxinA.

Keywords

Neurogenic detrusor overactive bladder Idiopathic overactive bladder Meta-analysis OnabotulinumtoxinA 

Notes

Acknowledgements

Hospital funding only by the research fund of Hanyang University (HY-2017).

Authors’ contribution

JKJ: study design, data acquisition, analysis and interpretation of data, and writing of the article; KNK: study design, data acquisition, analysis and interpretation of data, and writing of the article; DWK: data acquisition and interpretation of data; YTK: data acquisition; JYK: organizing data; JYK: organizing data and preparing manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

References

  1. 1.
    Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21(2):167–178CrossRefPubMedGoogle Scholar
  2. 2.
    Sacco E, Tienforti D, D’Addessi A, Pinto F, Racioppi M, Totaro A, D’Agostino D, Marangi F, Bassi P (2010) Social, economic, and health utility considerations in the treatment of overactive bladder. Open Access J Urol 2:11–24CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50(6):1306–1314.  https://doi.org/10.1016/j.eururo.2006.09.019 (discussion 1314–1305) CrossRefPubMedGoogle Scholar
  4. 4.
    Onukwugha E, Zuckerman IH, McNally D, Coyne KS, Vats V, Mullins CD (2009) The total economic burden of overactive bladder in the United States: a disease-specific approach. Am J Manag Care 15(4 Suppl):S90–S97PubMedGoogle Scholar
  5. 5.
    Garely AD, Burrows LJ (2002) Current pharmacotherapeutic strategies for overactive bladder. Expert Opin Pharmacother 3(7):827–833.  https://doi.org/10.1517/14656566.3.7.827 CrossRefPubMedGoogle Scholar
  6. 6.
    Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20(6):327–336.  https://doi.org/10.1007/s00345-002-0301-4 PubMedGoogle Scholar
  7. 7.
    Chapple CR (2000) Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 55(5A Suppl):33–46 (discussion 50) CrossRefPubMedGoogle Scholar
  8. 8.
    Cameron AP (2010) Pharmacologic therapy for the neurogenic bladder. Urol Clinic N Am 37(4):495–506.  https://doi.org/10.1016/j.ucl.2010.06.004 CrossRefGoogle Scholar
  9. 9.
    Brostrom S, Hallas J (2009) Persistence of antimuscarinic drug use. Eur J Clin Pharmacol 65(3):309–314.  https://doi.org/10.1007/s00228-008-0600-9 CrossRefPubMedGoogle Scholar
  10. 10.
    Sexton CC, Notte SM, Maroulis C, Dmochowski RR, Cardozo L, Subramanian D, Coyne KS (2011) Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract 65(5):567–585.  https://doi.org/10.1111/j.1742-1241.2010.02626.x CrossRefPubMedGoogle Scholar
  11. 11.
    Grosse J, Kramer G, Stohrer M (2005) Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 47(5):653–659.  https://doi.org/10.1016/j.eururo.2004.11.009 CrossRefPubMedGoogle Scholar
  12. 12.
    Bagi P, Biering-Sorensen F (2004) Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions. Scand J Urol Nephrol 38(6):495–498.  https://doi.org/10.1080/00365590410015867 CrossRefPubMedGoogle Scholar
  13. 13.
    Jundt K, Schreyer K, Friese K, Peschers U (2011) Anticholinergic therapy: do the patients take the pills prescribed? Arch Gynecol Obstet 284(3):663–666.  https://doi.org/10.1007/s00404-010-1720-x CrossRefPubMedGoogle Scholar
  14. 14.
    Higgins JP, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration. http://handbook.cochrane.org. Accessed Apr 2017
  15. 15.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(6):557–560.  https://doi.org/10.1136/bmj.327.7414.557 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Hui C, Keji X, Chonghe J, Ping T, Rubiao O, Jianweng Z, Xiangrong D, Liling Z, Maping H, Qingqing L, Qiuling L, Jiebing H, Tanghai H (2016) Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity. Spinal Cord 54(1):46–50.  https://doi.org/10.1038/sc.2015.143 CrossRefPubMedGoogle Scholar
  17. 17.
    Huang M, Chen H, Jiang C, Xie K, Tang P, Ou R, Zeng J, Liu Q, Li Q, Huang J, Huang T, Zeng W (2016) Effects of botulinum toxin A injections in spinal cord injury patients with detrusor overactivity and detrusor sphincter dyssynergia. J Rehabil Med 48(8):683–687.  https://doi.org/10.2340/16501977-2132 CrossRefPubMedGoogle Scholar
  18. 18.
    Kuo HC (2011) Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn 30(7):1242–1248.  https://doi.org/10.1002/nau.21054 PubMedGoogle Scholar
  19. 19.
    Manecksha RP, Cullen IM, Ahmad S, McNeill G, Flynn R, McDermott TE, Grainger R, Thornhill JA (2012) Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity. Eur Urol 61(5):928–935.  https://doi.org/10.1016/j.eururo.2011.10.043 CrossRefPubMedGoogle Scholar
  20. 20.
    Abdel-Meguid TA (2010) Botulinum toxin-A injections into neurogenic overactive bladder—to include or exclude the trigone? A prospective, randomized, controlled trial. J Urol 184(6):2423–2428.  https://doi.org/10.1016/j.juro.2010.08.028 CrossRefPubMedGoogle Scholar
  21. 21.
    Krhut J, Samal V, Nemec D, Zvara P (2012) Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: a pilot study. Spinal Cord 50(12):904–907.  https://doi.org/10.1038/sc.2012.76 CrossRefPubMedGoogle Scholar
  22. 22.
    Kuo HC (2007) Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J Urol 178(4 Pt 1):1359–1363.  https://doi.org/10.1016/j.juro.2007.05.136 CrossRefPubMedGoogle Scholar
  23. 23.
    Samal V, Mecl J, Sram J (2013) Submucosal administration of onabotulinumtoxinA in the treatment of neurogenic detrusor overactivity: pilot single-centre experience and comparison with standard injection into the detrusor. Urol Int 91(4):423–428.  https://doi.org/10.1159/000350247 CrossRefPubMedGoogle Scholar
  24. 24.
    Purves JT, Spruill L, Rovner E, Borisko E, McCants A, Mugo E, Wingard A, Trusk TC, Bacro T, Hughes FM Jr (2017) A three dimensional nerve map of human bladder trigone. Neurourol Urodyn 36(4):1015–1019.  https://doi.org/10.1002/nau.23049 CrossRefPubMedGoogle Scholar
  25. 25.
    Andersson KE (2002) Bladder activation: afferent mechanisms. Urology 59(5 Suppl 1):43–50CrossRefPubMedGoogle Scholar
  26. 26.
    Klein LA (1988) Urge incontinence can be a disease of bladder sensors. J Urol 139(5):1010–1014CrossRefPubMedGoogle Scholar
  27. 27.
    Kuo HC (2006) Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? Urology 68(5):993–997.  https://doi.org/10.1016/j.urology.2006.05.054 (discussion 997–998) CrossRefPubMedGoogle Scholar
  28. 28.
    Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, Daniell G, Zhou J, Haag-Molkenteller C (2010) Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 184(6):2416–2422.  https://doi.org/10.1016/j.juro.2010.08.021 CrossRefPubMedGoogle Scholar
  29. 29.
    Mehnert U, Boy S, Schmid M, Reitz A, von Hessling A, Hodler J, Schurch B (2009) A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging. World J Urol 27(3):397–403.  https://doi.org/10.1007/s00345-008-0362-0 CrossRefPubMedGoogle Scholar
  30. 30.
    Kjaergard LL, Villumsen J, Gluud C (2001) Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 135(11):982–989CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2017

Authors and Affiliations

  1. 1.Department of Urology, College of MedicineHanyang UniversitySeoulKorea
  2. 2.Department of Anesthesiology and Pain Medicine, College of MedicineHanyang UniversitySeoulKorea
  3. 3.Department of Anesthesiology and Pain MedicineHanyang University HospitalSeoulRepublic of Korea

Personalised recommendations